Trackk Logo
Trackk Logo
Blogs / Laurus Labs Share Pr...

Laurus Labs Share Price Target 2025, 2026, 2027, 2030

2026-05-18 · 3 min read

Sector - Finance
Laurus Labs Share Price Target 2025, 2026, 2027, 2030

Laurus Labs Ltd has quietly moved from being viewed as an antiretroviral-focused API company to a broader pharmaceutical manufacturing and CDMO platform. 

Laurus Labs Share Price Target


The stock has also made a strong comeback, helped by margin recovery, better CDMO execution, operating leverage, and renewed investor interest in pharma manufacturing. 

Financial table for Laurus Labs

Market Cap₹62,861 Cr.(As of May 2026)
Price to Earnings70.7
Return on equity18.2%
Debt to equity0.48
Current ratio1.33
Dividend Yield0.17%
Return on assets8.97%
ROCE17.7%
Face Value₹2.00
52 Week High₹1,177
52 Week Low₹572

Laurus Labs Shareholding Pattern



Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Promoters

32.04%

27.45%

27.27%

27.20%

27.18%

27.62%

27.49%

FIIs

11.29%

20.68%

22.45%

22.42%

25.98%

25.51%

25.82%

DIIs

31.59%

3.56%

7.93%

9.74%

11.78%

11.78%

13.96%

Public

25.08%

48.31%

42.36%

40.64%

35.07%

35.07%

32.73%

No. of Shareholders

45,507 

2,35,836 

4,27,465 

4,18,615 

3,56,830 

2,92,905 

2,92,281 


Laurus Labs Price Target 2026, 2027, 2028 to 2030

YEAR 2026

Target Range (₹) : 1200-1500

for the move CDMO growth and capex support steady expansion. Projected Targets:
YEAR 2027

Target Range (₹) : 1600-2200

for the move KRKA JV and operating leverage improve earnings. Projected Targets:
YEAR 2028

Target Range (₹) : 1200-1500

for the move Transition remains gradual. Projected Targets:
YEAR 2029

Target Range (₹) : 1600-1800

for the move .Margins improve steadily. Projected Targets:
YEAR 2030

Target Range (₹) : 2000-2100

for the move Integrated pharma and CDMO model ensures strong long-term growth.

Historic Performance:

Laurus Labs Share Price Target 2020, 2021, 2022, 2023, 2024 & 2025

YEAR 2020

Yearly returns : 393.23%

Start of the year price71.60
End of the year price353.15
Reason : Massive rally driven by COVID-related pharma demand and ARV strength.
YEAR 2021

Yearly returns : 51.89%

Start of the year price354.80
End of the year price538.90
Reason : API and formulations business performed strongly.
YEAR 2022

Yearly returns : -30.96%

Start of the year price543.50
End of the year price375.25
Reason : Sharp correction due to normalization post-COVID demand.
YEAR 2023

Yearly returns : 14.13%

Start of the year price376.95
End of the year price430.20
Reason : Early signs of diversification supported sentiment.
YEAR 2024

Yearly returns : 39.84%

Start of the year price431.00
End of the year price602.70
Reason : Strong growth driven by CDMO expansion and improved margins.
YEAR 2025

Yearly returns : 83.13%

Start of the year price605.05
End of the year price1,108.00
Reason : Improved growth visibility and expansion plans boosted valuation.

Conclusion

The Laurus Labs share price target depends mainly on CDMO growth, margin sustainability, and valuation comfort.

FAQs

To read the RA disclaimer, please click here